The US Food and Drug Administration has cleared the first clinical trials of gene-edited pig kidneys in humans, moving cross-species transplantation from one-off experiments into formal testing. In September 2026 the agency granted approval for eGenesis to run a phase one, two and three trial of its EGEN-2784 pig kidney, with 33 patients aged 50 to 70 starting in early 2027 at up to 30 centres. United Therapeutics began a trial of its UKidney in November 2026, starting with six patients and potentially rising to 50. The organs come from pigs with heavily edited genes: the United Therapeutics pig carries 10 edits, while the eGenesis pig carries 69, including inactivation of porcine viruses that could infect humans. Earlier patients treated under compassionate use showed the idea can work. Tim Andrews, 67, lived without dialysis for nine months after receiving a pig kidney in January 2025, then received a human kidney in January 2026, the first case of a pig organ acting as a bridge to a human transplant.
What the Evidence Shows
The trials are a response to a severe shortage of human organs: far more people need kidneys than donors can supply, and many spend years on dialysis. The longest-surviving pig kidney recipient so far is Towana Looney, a 53-year-old woman from Alabama who received her transplant at NYU Langone Health in November 2024. Five patients at Mass General Brigham have now received eGenesis pig kidneys under expanded access, and one, Bill Stewart, was discharged just a week after surgery in June 2025. The trials will test safety and organ function over months rather than weeks, and the answers will not arrive quickly. No gene-edited pig organ is approved for routine treatment, and risks remain, including rejection and infection. United Therapeutics has also begun a very small trial of pig heart transplants. Reporting and analysis from sources such as World Health Organization track the same developments, and specialists following gene-edited pig kidney transplants say the direction is now consistent across independent lines of evidence.
The Wider Context
The wider context is a health system trying to move from treating illness late to preventing it early, against budgets that reward the opposite. Evidence around gene-edited pig kidney transplants is being weighed by guideline committees that ask two questions in order: does it work, and can ordinary services actually deliver it at scale. Many good ideas pass the first test and stall on the second.
What Happens Next
What happens next for gene-edited pig kidney transplants depends on the slow machinery of guidelines, funding and training catching up with the evidence. Patients asking about it today should expect honest answers that include uncertainty, and clinicians say a service that explains what is not yet known earns more trust than one that oversells. The research pipeline, at least, is moving in the right direction. You can follow related developments in our coverage of health.
There is a practical lesson in all of this for readers deciding what to do today. Start with the verified facts, be wary of anyone promising certainty, and prefer reversible steps while the evidence is still developing. Circumstances differ by country, income and personal situation, so general guidance should always be weighed against your own context before you act on it in any significant or lasting way.